Columbia Brain Imaging Research Suspended

The New York Times reports (below) that FDA " investigators found that Columbia had routinely injected mental patients with drugs that contained potentially dangerous impurities."  Columbia had "repeatedly violated FDA [safety] regulations over a four-year period."

The issue involves radioactive compounds which, although considered to be safe,  they degrade quickly. Thus, many laboratories produce them themselves, under protocols agreed upon with the F.D.A which sets allowable radiation levels and standards of purity for the injected drugs. The Times reports that: "If a drug contains too many impurities — unknown chemicals that may or may not be related to the tracer itself — then its effects in the body are unpredictable."

The FDA investigation found "at least 10 batches" of drugs had been "released and injected into human subjects" with impurities that exceeded the level the lab had agreed to set. At least four injections "had impurity masses that more than doubled the maximum limit implemented."

In December 2008, the FDA warned Columbia that "failure to promptly correct these violations may result in legal action without further notice." Columbia administrators ignored the warning.

According to an employee’s letter of resignation (2009): "These are not actions of a rogue, but instead are systematic forgeries condoned and approved by the lab director."

When FDA investigators returned in January 2010, “They raided the place like it was a crime scene, seizing hard drives,” said one former lab worker, who requested anonymity because he feared reprisals from the university.

The FDA raid yielded hard evidence and a long list of specific serious violations:
the lab failed to check "the identity, strength and purity of each active ingredient prior to release" for injections into patients.

The researchers undermined both patient safety and the scientific validity of the research–rendering the Columbia’s PET research invalid and unethical.

The radiotracers used in many of the Columbia studies–unlike other PET drugs–are more prone to be biologically active–they target brain receptors. So, Columbia’s failure to ensure quality control is downright reckless and irresponsible.

Indeed, radiation experts at the University of Pittsburgh and Washington, St. Louis are highly critical of Columbia’s disregard for patients’ safety.
Dr. dennis Swanson, chairman of radiation safety commission (U. Pittsburgh): "You have to have additional quality-assurance procedures if you’r using agents that bind receptors to the brain." 

Dr. Barry Siegel, chairman of the radioactive drug research committee at Washington University in St. Louis, puts it this way:   “There could be a patient safety issue, for one, and there could be a scientific validity issue. If you’re exposing people to radiation and getting garbage data, then that becomes an ethical problem.”

This is not the first time that Columbia’s medical research–in particular, its psychiatric research–has been found in violation of federally mandated research safeguards. Columbia researchers have routinely exploited the vulnerability of mental patients and children of color with impunity, using them in commercially-driven experiments that have been shown to be dubious both ethically and scientifically. The experiments offered no benefit to the subjects, while putting them at unjustifiable risk of harm and (at the very least) discomfort. 

However, Columbia’s substantial influence shielded the researchers and the medical center from being held accountable.

For example, Columbia’s psychiatric researchers have an ignoble record of violating informed consent regulations.
See: TD v NYS OMH , 1995
See also: Incapacitated Research by Alexander Morgan Capron
(NYS Psych Institute is part of the Columbia medical center campus where Columbia’s psychiatry faculty conduct most clinical research)

Another example: the pseudo-scientific predisposition to violence experiments in which Black and Hispanic children aged 6 to 11 were exposed to fenfluramine because psychiatrists hypothesized that they were predisposed to violence–in the future.
See: Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present By Harriet A. Washington. Random House.
 
Another example: a federal investigation found that Columbia violated federal safeguard requirements for children when its researchers conducted AIDS drug and vaccine experiments on poor children in foster care without providing them with an independent advocate–i.e., surrogate parent–as mandated by federal rules.
See:  Complaint filed by AHRPwith the Office of Human Research Protections:
And the OHRP determination letter validating the AHRP complaint:

And see: Guinea Pig Kids , synopsis at Institute for Science and Society.


THE NEW YORK TIMES
July 16, 2010
Studies Halted at Brain Lab Over Impure Injections
By BENEDICT CAREY

Columbia University has quietly suspended research at a nationally prominent brain-imaging center and reassigned its top managers after federal investigators found that it had routinely injected mental patients with drugs that contained potentially dangerous impurities.

The investigations found that the center — regarded by experts as the nation’s leader in the use of positron emission tomography, or PET, for psychiatric research — repeatedly violated Food and Drug Administration regulations over a four-year period.

“Failure to promptly correct these violations may result in legal action without further notice,” the agency wrote to Columbia in December 2008, citing lax internal quality control and sloppy procedures for formulating drug injections.

F.D.A. investigators returned in January 2010 and found that many of the center’s lab’s practices had not changed, and cited a long list of specific violations, including one instance in which the staff hid impurities from auditors by falsifying documents.

“They raided the place like it was a crime scene, seizing hard drives,” said one former lab worker, who requested anonymity because he feared reprisals from the university.

In a statement, the university said on Friday that it had conducted its own investigation of the lab at the request of the F.D.A. had and reported to the agency on July 6 that it found no evidence of harm to patients. The F.D.A. did not publicize its investigations; The New York Times learned of them from doctors who were familiar with the lab’s problems.

The office under fire, the Kreitchman PET Center, on West 168th Street in Manhattan, has attracted millions of dollars in research funds from the federal government and pharmaceutical companies to study drug actions and the biology of brain disorders, among other things.

Many of its studies focus on patients with disorders like schizophrenia and severe depression, who are especially vulnerable to poorly prepared imaging drugs because the compounds can act on brain receptors involved in their illness.

“We acknowledge serious shortcomings of quality control in the manufacturing process and record-keeping at this lab,” said David I. Hirsh, Columbia’s executive vice president for research. “That is why we are fundamentally reorganizing the lab’s management and operations in response to what the F.D.A. told us.”

To perform a PET scan, doctors must first inject patients with a radiotracer, a drug engineered to accumulate in the area of the body being studied and to emit low-level radiation detectable by a scanner.

The compounds are considered very safe. But because they degrade quickly, many laboratories produce them themselves, under protocols agreed upon with the F.D.A.

The agency regulates the allowable radiation levels and the purity of the drugs. If a drug contains too many impurities — unknown chemicals that may or may not be related to the tracer itself — then its effects in the body are unpredictable.

“There could be a patient safety issue, for one,” said Dr. Barry Siegel, chairman of the radioactive drug research committee at Washington University in St. Louis. “And there could be a scientific validity issue. If you’re exposing people to radiation and getting garbage data, then that becomes an ethical problem.”

That is particularly true when it comes to psychiatric research. Radiotracers that target receptors in the brain, as used in many of the Columbia studies, are more prone than other PET drugs to be biologically active — to affect mood or behavior, especially in those who already suffer from severe depression or other mental problems. “You have to have additional quality-assurance procedures if you’re using agents that bind receptors in brain,” said Dr. Dennis P. Swanson, chairman of the radiation safety commission at the University of Pittsburgh.

The F.D.A.’s latest investigation, which took place from Jan. 5 to Jan. 21, listed six categories of violations. It found that since 2007, “at least 10 batches” of drugs had been “released and injected into human subjects” with impurities that exceeded the level the lab had agreed to set. At least four injections “had impurity masses that more than doubled the maximum limit implemented.”

The report highlighted an equation that the lab routinely used, resulting in injections that exceeded the limit for acceptable impurities. The lab did not adequately check “the identity, strength and purity of each active ingredient prior to release” for injection into patients, the report said.

Agency investigators also found a forged document, a hard copy record that had been altered to hide a drug impurity that showed up clearly in the computer records.

Former employees, speaking on the condition of anonymity because they worked in the imaging field or hoped to, said those practices were not only commonplace but also condoned. They described a center under such pressure to produce studies that it papered over and hid impurities in drugs to stretch its resources and went ahead with business as usual despite F.D.A. warnings.

“These are not the actions of a rogue, but instead are systematic forgeries condoned and approved by the lab director,” wrote one employee in a 2009 resignation letter addressed to Dr. Ronald L. Van Heertum, the PET center’s co-director at the time.

Columbia’s internal audit concluded that this and other charges had “sufficient substance to warrant an investigation,” according to documents obtained by The Times. Among the charges was one that the lab replaced a compound it was testing for the drug maker Eli Lilly with one it was testing for Novartis — and did not mention the switch in its report to Eli Lilly.

Neither Dr. Van Heertum, a radiologist, nor his former co-director, Dr. J. John Mann, a psychiatrist, returned calls seeking comment on Friday.

In his statement, Dr. Hirsh said, “When manufacturing resumes under new leadership, it will meet the strictest standards and best practices for ensuring the quality” of the PET drugs.

He said the center’s clinical, nonresearch side was not affected by the suspension, adding that it was “fully approved and operational” and remained open for patient care.